Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDRStenotrophomonas maltophilia | Zendy

Monika Kumaraswamy | Zendy; Leo Lin | Zendy; Joshua Olson | Zendy; Ching-Fang Sun | Zendy; Poochit juie | Zendy; Ross Corriden | Zendy; Simon Döhrmann | Zendy; Syed R. Ali | Zendy; Deirdre Amaro | Zendy; Manfred Rohde | Zendy; Joe Pogliano | Zendy; George Sakoulas | Zendy; Victor Nizet | Zendy

Open Access

Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDRStenotrophomonas maltophilia

Author(s) -

Monika Kumaraswamy,

Leo Lin,

Joshua Olson,

Ching-Fang Sun,

Poochit juie,

Ross Corriden,

Simon Döhrmann,

Syed R. Ali,

Deirdre Amaro,

Manfred Rohde,

Joe Pogliano,

George Sakoulas,

Victor Nizet

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv487

Subject(s) - stenotrophomonas maltophilia , azithromycin , microbiology and biotechnology , stenotrophomonas , biology , pathogen , gram negative bacteria , bacteria , pseudomonas aeruginosa , antibiotics , pseudomonas , escherichia coli , biochemistry , genetics , gene

The Gram-negative bacillus Stenotrophomonas maltophilia (SM) is an emerging MDR opportunistic pathogen. Recent studies identify a potentially relevant activity of azithromycin against Gram-negative bacteria overlooked in standard bacteriological testing. We investigated azithromycin activity against SM in testing conditions incorporating mammalian tissue culture medium and host defence factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research